Collegium Announces Poster Presentations for Xtampza™ ER at the International Conference on Opioids
CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on the use of Xtampza ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the International Conference on Opioids, which will be held in Boston on June 5-7, 2016.
Details of the poster presentations are as follows:
Date: Monday, June 6, 2016
Times: 10:00-10:30 am, 12:30-1:30 pm, and 3:30-4:00 pm ET
Location: The Joseph B. Martin Conference Center at Harvard Medical School
Poster #49: “Safety, Tolerability, and Efficacy of Xtampza™ ER (Oxycodone DETERx® extended-release) Treatment in Subjects 65 Years and Older”
Poster #50: “Sprinkle Administration of Xtampza™ ER (Oxycodone DETERx® extended-release): An Abuse-deterrent, Extended-release Formulation”
For more information on the International Conference on Opioids, visit http://www.opioidconference.org/ .
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza™ ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
For Important Safety Information Visit, http://www.xtampzaer.com/
Contact: Douglas Carlson Vice President, Corporate Development dcarlson@collegiumpharma.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
